Humacyte, Inc. HUMA 深 滬
已收盤 04-02 16:00:00 美东时间
0.6424
+0.051
+8.53%
華盛通- 最 高0.6575
- 今 開0.5813
- 成交量 481.96万股
- 最 低 0.575
- 昨 收 0.5919
- 總市值 1.43亿
- 52周最高 2.93
- 市盈率 靜 --
- 換手率 2.17%
- 52周最低 0.5469
- 委 比 89.79%
- 總股本 2.22亿
- 歷史最高 17.45
- 量 比 0.48
- 振 幅 13.94%
- 歷史最低 0.5469
- 每 手 1
- 風險率 0.53%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
This Rockwell Automation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Top Wall Street analysts changed outlook on top names. Needham downgrades CNTA, Baird downgrades PHR.
04-01 00:00
美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
美股大行评级 | 能源股再或大行青睐！康菲石油、雪铁龙、埃克森美孚、响尾蛇能源等获上调目标价；Unity评级分歧大，大摩、美银上调，富国银行下调
今日重点评级关注：花旗：维持Biomea Fusion"买入"评级，目标价从6美元升至7美元；Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.75美元升至8.25美元
03-30 11:49
BTIG Maintains Buy on Humacyte, Lowers Price Target to $3
BTIG analyst Ryan Zimmerman maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price target from $6 to $3.
03-27 22:39
Earnings Scheduled For March 27, 2026
Companies Reporting Before The Bell • Instil Bio (NASDAQ:TIL) is expected to re...
03-27 19:11
Humacyte Commences $20M Offering Of 25M Common Stock
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has entered into a securities
03-19 20:35
Humacyte Receives $1.475M Commitment Of Symvess Acellular Tissue Engineered Vessel For Facilitation Of Hospitals In Saudi Arabia
Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has received a minimum purchase
03-19 20:34
Humacyte Reports Data Evaluating Symvess In Extremity Arterial Trauma Patients
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of long-term data
02-18 21:15
美股牛股 | 华仕伯大涨超34%！有望获Transocean以58亿美元收购；Playboy涨超33%
华仕伯大涨超34%！有望获Transocean以58亿美元收购，打造领先海上钻井巨头；Playboy涨超33%，拟1.22亿美元出售50%中国业务；脉冲生物科学涨超16%>>
02-10 15:18
